Abstract: 1-Carba(1-dethia)cephem antibacterial agents possessing a 3-(substituted or unsubstituted)thiazolo group are provided. Further provided is a method for treating bacterial infections in man and other animals and a pharmaceutical formulation utilziing said 1-carba(1-dethia)cephems.

Abstract: The present invention provides a process for protecting an amino group in a compound exposed to nucleophilic reaction conditions in which the imido group used for protection is reacted with a secondary amine to form an acyl group which protects the amino group during exposure to the nucleophilic reaction conditions, after which the acylamino group may be reacted with an acid to reform the imido group so that the compound may then undergo non-nucleophilic manipulations. Also provided is a resolution method in which diasteriometric compounds having the acylamino group as described above are reacted with acid, and as these diasteriomers react at different rates to form the imido group, the reaction may be monitored so as to isolate the desired product at the appropriate point to maximize optical purity.

Abstract: Disclosed is a process using hydrolysis and hydrogenation for converting enamino .beta.-lactams to their saturated alkyl ester acid salts, key intermediates to 1-carbacephalosporins. Also disclosed are intermediates resulting from the process.

Abstract: A method for preparing 2-amino-.beta.-lactams which are substituted by readily-removed protecting groups is provided. According to this invention, an acyl-2-amino-.beta.-lactam is further acylated with a different acyl group and is subsequently treated with base to provide a protected 2-amino .beta.-lactam with a more desirable protecting group.

Abstract: Cephalosporin and 1-carba(1-dethia)cephalosporin antibiotics substituted in the 3-position with, inter alia, alkyl, alkenyl and alkynyl, are provided via process comprising conversion of a cephalosporin or 1-carba(1-dethia)-3-cephem substituted in the 3-position with halogen or a sulfonyloxy ester with Pd(O) mediated alkylation with organostannanes.

Abstract: 3-Exomethylenecepham sulfoxide esters are obtained in improved yields via cyclization of 3-methyl-2-(4-chlorosulfinyl-2-oxo-3-amino-1-azetidinyl)-3-butenoic acid esters under anhydrous conditions with a Lewis acid-type Friedel-Crafts catalyst in the presence of a nitro compound, e.g., nitromethane, nitroethane, nitropropane or nitrobenzene.

Abstract: The invention provides novel compounds of the formula ##STR1## wherein R is a protected amino group and R1 is a carboxy protected group.

Abstract: A process for preparing 3-4-cis-.beta.,.beta.-(4)-substituted and 3-4-trans,.beta.,.alpha.-(4)-substituted azetidinones is provided. Also provided are novel 4,4-disubstituted azetidinones.

Abstract: 7-.beta.-Acylamino-1-carba-(1-dethia)-3-trifluoromethyl-3-cephem-4-carboxyl ic acids and derivatives are provided as antibiotics. Pharmaceutical formulations comprising the antibiotics, intermediates, and a process for their preparation are also provided.

Abstract: Chiral epoxybutyrates are prepared in high yield from novel dihydro-3R-substituted sulfonyloxy-4R-hydroxy-2-(3H)furanones via based catalyzed alcoholysis. The product chiral epoxy butyrates are useful intermediates for the synthesis of 1-carba-1-dethia cephem antibiotics.

Abstract: The crystalline monohydrate, mono (N,N'-dimethylformamide) and bis(N,N'-dimethylformamide) solvates of 7.beta.-[2'-(R)-2'-(p-hydroxyphenyl-2'-amino-acetamido]-3-chloro-3-(1-carb adethiacephem)-4-carboxylic acid ("LY213735") are novel compounds with superior physical characteristics. Also described are pharmaceutical formulations of crystalline LY213735 monohydrate.

Abstract: The invention provides a process for preparing 7-protected amino-4-protected carboxy-1-carbacephalosporins which includes subjecting a 3-protected-amino-4-(1-propylene oxide)-methyl(protected carboxy)-azetidin-2-one to a strong base to form a 2-hydroxycepham and thereafter dehydrating the 2-hydroxycepham to form the desired 1-carbacephalosporin.

Abstract: An improved process for preparing trialkylsilyl ester and acid halide derivatives of carboxylic acids is provided along with novel trialkylsilyl ester intermediates of 2-(2-furyl)-2-methoximinoacetic acid.

Abstract: This invention provides novel 3-phosphine oxide substituted 1-carba(1-dethia)cephalosporins useful as anti-microbial agents, and formulations and methods of use thereof.

Abstract: The present invention provides compounds of the formula ##STR1## wherein R is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.6 haloalkyl;A and A' are independently hydrogen, C.sub.1 -C.sub.6 alkyl, nitro, amino, a 5-6 membered organic heterocycle containing 1, 2 or 3 hetero atoms selected from nitrogen or sulfur, C.sub.1 -C.sub.6 alkoxy, or phenyl; or A and A' taken together form a group of the formulae ##STR2## wherein X is hydrogen, halo, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, nitro, or carboxy; and Y is nitrogen or carbon; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions and methods of treatment using the above compounds.

Abstract: A ring-puller tool for quickly and effectively removing a prophylactyic shroud having a flexible ring attached thereto and positioned on a vial containing medicament.

Abstract: The invention provides a free radical process for preparing 1-carba(1-dethia)cephalosporin antibiotics with 2-substituted methylcephalosporin 1,1-dioxides wherein the substituent on the 2-methylene group is a free radical precursor group such as a phenyl or alkylseleno group. The latter dioxides are treated with a free radical initiator, e.g., a trialkyltin hydride or actinic radiation at 40.degree. C. to 150.degree. C. to provide the 1-carba-3-cephem and 1-carba-2-cephem products. The invention also provides free radical compounds formed as intermediates in the process.

Abstract: An improvement in the process of preparing ceftazidime pentahydrate from ceftazidime dihydrobromide which comprises commingling a secondary-amine-type ion-exchange resin such as Amberlite LA-2 in a water-immiscible organic solvent with an aqueous solution of the dihydrobromide, stirring the mixture while maintaining a pH at or below about 6.0 and isolating ceftazidime pentahydrate from the aqueous layer. This process provides significantly higher yields of the pentahydrate than previously could be obtained from the dihydrobromide.

Abstract: This invention relates to antibacterial compounds of the formula ##STR1## wherein A is hydrogen or an acyl group ##STR2## R.sub.a is a negative charge; R.sub.z is hydrogen, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, or a formamido group, --NHCHO; and --N.sup..sym. .tbd.Y is a quarternary ammonium group that may be acyclic, cyclic, or a combination of the two, and may contain on or more additional hetero atoms selected from nitrogen, sulfur and oxygen; and pharmaceutically acceptable non-toxic salts thereof.

Abstract: An improved process for preparing trialkylsilyl ester and acid halide derivatives of carboxylic acids is provided along with novel trialkylsilyl ester intermediates of 2-(2-furyl)-2-methoximinoacetic acid.